A5103241521- Chronic Lymphocytic Leukemia Research
- DNA Repair Mechanisms
- RNA Interference and Gene Delivery
- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- MicroRNA in disease regulation
- Protein Degradation and Inhibitors
- DNA and Nucleic Acid Chemistry
- Advanced biosensing and bioanalysis techniques
- RNA modifications and cancer
- Synthesis of Organic Compounds
- Chronic Myeloid Leukemia Treatments
- Synthesis and biological activity
- Free Radicals and Antioxidants
- Phagocytosis and Immune Regulation
- Retinal Development and Disorders
- Circular RNAs in diseases
- Advanced Electron Microscopy Techniques and Applications
- Cell death mechanisms and regulation
- Fungal Infections and Studies
- Zebrafish Biomedical Research Applications
- PARP inhibition in cancer therapy
- Advanced Fluorescence Microscopy Techniques
- Glioma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
The University of Texas MD Anderson Cancer Center
2013-2024
University of Florida
2013-2016
Cancer Genetics (United States)
2014-2016
UF Health Cancer Center
2015
University of Florida Health
2015
Second Military Medical University
2006-2012
University of Rochester Medical Center
2008-2011
TherapeuticsMD (United States)
2011
Liaocheng Center for Disease Control and Prevention
2010
Fudan University
2010
Abstract Purpose: The double-strand breaks elicited by sapacitabine, a clinically active nucleoside analogue prodrug, are repaired RAD51 and the homologous recombination repair (HR) pathway, which could potentially limit its toxicity. We investigated mechanism histone deacetylase (HDAC) inhibitors targeted HR to sensitize acute myelogenous leukemia (AML) cells sapacitabine. Experimental Design: Chromatin immunoprecipitation identified role of HDACs in silencing miR-182 AML. Immunoblotting,...
Rx is a paired-like homeobox gene that required for vertebrate eye formation. Mice lacking function do not develop eyes or the posterior pituitary. To determine whether cell autonomously in these tissues, we generated embryonic chimeras consisting of wild type and Rx-/- cells. We found eye, Rx-deficient cells cannot participate formation neuroretina, retina pigment epithelium distal part optic stalk. In addition, ventral forebrain, Interestingly, segregate before morphogenesis two tissues...
Most human pancreatic cancer cells are resistant to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. However, the mechanisms by which utilize their extracellular molecules counteract proapoptotic signaling mediated TNF family largely unknown. In this study, we demonstrate for first time that DcR3, a secreted decoy receptor malignant express at high level, acts as an antiapoptotic molecule binding TRAIL and counteracting its death-promoting function....
// Cecelia R. Miller 1 , Amy S. Ruppert Sydney Fobare 1,2 Timothy L. Chen Chaomei Liu 3 Lehman 4 James Blachly Xiaoli Zhang David M. Lucas Michael Grever Martin Tallman 5 Ian W. Flinn 6 Laura Z. Rassenti 7,9 Thomas J. Kipps Deepa Sampath Kevin Coombes 8,* and Erin K. Hertlein 1,* Department of Internal Medicine, Division Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA 2 Hendrix College, Conway, AR, Experimental Therapeutics, MD Anderson University...
The constitutive activation of B-cell receptor (BCR) signaling, together with the overexpression Bcl-2 family anti-apoptotic proteins, represents two hallmarks chronic lymphocytic leukemia (CLL) that drive cell proliferation and sustain their survival. TG02 is a small molecule multi-kinase inhibitor simultaneously targets both these facets CLL pathogenesis. First, its inhibition cyclin-dependent kinase 9 blocked RNA polymerase II transcription. This led to depletion Mcl-1 rapid induction...
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment the Bcell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity BCL2 targeting, but durability of response remains a concern. We hypothesize that targeting both and B-cell lymphoma-extra large (BCLXL) will be successful strategy treat CLL, including for patients who relapse on To test this hypothesis, we conducted pre-clinical investigation LP-118, highly potent moderate BCLXL...
Incorporation of the clinically active deoxycytidine analogue 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosyl-cytosine (CNDAC) into DNA generates single-strand breaks that are subsequently converted to double-strand (DSB). Here, we investigated cellular manifestations these link mechanisms cell death, and further tested relevance repair pathways in protection cells against CNDAC damage. The present investigations demonstrate following exposure a wash drug-free medium, chromosomal...